Evidence map›Paper›PMID 26152583›Full record

ArticlemBio2015

The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.

Guillaume Mousseau, Cari F Kessing, Rémi Fromentin, Lydie Trautmann, Nicolas Chomont, Susana T Valente

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in mBio, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04263207 (Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response in Peripheral Blood HIV Reservoir Dynamics), which is not on this map. Cited by 176 papers.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04263207 suspendednot on this mapstarted 2020, after this paper: background citation

Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response in Peripheral Blood HIV Reservoir Dynamics

TypeobservationalSponsorBarbara Ensoli, MD, PhDRan2020 to 2025Enrolled100ConditionsHIV/AIDSArmsNo intervention
3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 226 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Searching for a HIV-1 Cure.Theranostics · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Engineering vaginal film platform for mucoadhesion and sustained drug release for HIV-1 prevention.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  20. Review

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Guillaume MousseauDepartment of Immunology and Microbial Sciences, The Scripps Research Institute, Jupiter, Florida, USA.
Cari F KessingVaccine and Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Rémi FromentinVaccine and Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Lydie TrautmannVaccine and Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Nicolas ChomontVaccine and Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Susana T ValenteDepartment of Immunology and Microbial Sciences, The Scripps Research Institute, Jupiter, Florida, USA svalente@scripps.edu.
Vaccine & Gene Therapy Institute of Florida · USScripps Research Institute · US

Funding

Mode of action of a new Tat HIV-1 inhibitorR01AI097012 · NIAID · UNIVERSITY OF FLORIDA · PI VALENTE, SUSANA T · 2012 to 2022
$7.5M
MOLECULAR BASIS OF VIRAL PATHOGENESIST32AI007354 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI DE LA TORRE, JUAN C. · 1989 to 2020
$5.2M
Towards HIV eradication using a novel Tat inhibitorR01AI118432 · NIAID · SCRIPPS FLORIDA · PI VALENTE, SUSANA T · 2015 to 2019
$2.3M
NIAID NIH HHS R01 AI097012NIAID NIH HHS R01AI097012NIAID NIH HHS R01 AI118432NIAID NIH HHS T32 AI007354
6 · The paper itself

Abstract

unlabelledAntiretroviral therapy (ART) inhibits HIV-1 replication, but the virus persists in latently infected resting memory CD4(+) T cells susceptible to viral reactivation. The virus-encoded early gene product Tat activates transcription of the viral genome and promotes exponential viral production. Here we show that the Tat inhibitor didehydro-cortistatin A (dCA), unlike other antiretrovirals, reduces residual levels of viral transcription in several models of HIV latency, breaks the Tat-mediated transcriptional feedback loop, and establishes a nearly permanent state of latency, which greatly diminishes the capacity for virus reactivation. Importantly, treatment with dCA induces inactivation of viral transcription even after its removal, suggesting that the HIV promoter is epigenetically repressed. Critically, dCA inhibits viral reactivation upon CD3/CD28 or prostratin stimulation of latently infected CD4(+) T cells from HIV-infected subjects receiving suppressive ART. Our results suggest that inclusion of a Tat inhibitor in current ART regimens may contribute to a functional HIV-1 cure by reducing low-level viremia and preventing viral reactivation from latent reservoirs. IMPORTANCE: Antiretroviral therapy (ART) reduces HIV-1 replication to very low levels, but the virus persists in latently infected memory CD4(+) T cells, representing a long-lasting source of resurgent virus upon ART interruption. Based on the mode of action of didehydro-cortistatin A (dCA), a Tat-dependent transcription inhibitor, our work highlights an alternative approach to current HIV-1 eradication strategies to decrease the latent reservoir. In our model, dCA blocks the Tat feedback loop initiated after low-level basal reactivation, blocking transcriptional elongation and hence viral production from latently infected cells. Therefore, dCA combined with ART would be aimed at delaying or halting ongoing viral replication, reactivation, and replenishment of the latent viral reservoir. Thus, the latent pool of cells in an infected individual would be stabilized, and death of the long-lived infected memory T cells would result in a continuous decay of this pool over time, possibly culminating in the long-awaited sterilizing cure.

Indexed as

Anti-HIV AgentsCD4-Positive T-LymphocytesCells, CulturedEpigenesis, GeneticGene Expression Regulation, ViralHeterocyclic Compounds, 4 or More RingsHIV-1HumansIsoquinolinesPromoter Regions, Genetictat Gene Products, Human Immunodeficiency VirusVirus LatencyAnti-HIV Agentsdidehydro-cortistatin AHeterocyclic Compounds, 4 or More RingsIsoquinolinestat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID26152583
PMCPMC4495168
OpenAlexW1926895509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.